Company intelligence / Profile preview

Panakeia

Cambridge, England, United Kingdompanakeiausa.com ↗

Ownership: Private
Development stage: Commercial

Overview

Panakeia has developed an AI-driven platform that enables rapid multiomics and biomarker profiling directly from routine H&E-stained tissue images. Their technology provides results in minutes rather than days or weeks and aims to accelerate precision medicine in oncology. The company recently launched the PANProfiler Colon tool for colon cancer and has presented blinded multi-site validation data at major scientific conferences.

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapy (AI-driven diagnostics)Device (software as a medical device)Platform (AI-based multiomics analysis platform)
Industry: Pathology

Partnerships

King's College LondonPathLAKELeeds UniversityTech Nation

Beyond the preview

Go deeper on Panakeia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panakeia.

Explore the full profile